TLPH vs. VINC, INDP, HUGE, TCRT, BIVI, APM, GLTO, BNTC, ORGS, and RNXT
Should you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Vincerx Pharma (VINC), Indaptus Therapeutics (INDP), FSD Pharma (HUGE), Alaunos Therapeutics (TCRT), BioVie (BIVI), Aptorum Group (APM), Galecto (GLTO), Benitec Biopharma (BNTC), Orgenesis (ORGS), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical preparations" industry.
Talphera (NASDAQ:TLPH) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.
Talphera has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
Talphera presently has a consensus target price of $6.00, suggesting a potential upside of 471.43%. Vincerx Pharma has a consensus target price of $5.00, suggesting a potential upside of 584.93%. Given Vincerx Pharma's higher probable upside, analysts clearly believe Vincerx Pharma is more favorable than Talphera.
In the previous week, Vincerx Pharma had 3 more articles in the media than Talphera. MarketBeat recorded 5 mentions for Vincerx Pharma and 2 mentions for Talphera. Talphera's average media sentiment score of 0.00 beat Vincerx Pharma's score of -0.25 indicating that Talphera is being referred to more favorably in the media.
Talphera has higher revenue and earnings than Vincerx Pharma. Talphera is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.
37.7% of Talphera shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 3.0% of Talphera shares are held by company insiders. Comparatively, 20.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Talphera's return on equity of -71.67% beat Vincerx Pharma's return on equity.
Vincerx Pharma received 18 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 64.52% of users gave Vincerx Pharma an outperform vote.
Summary
Talphera and Vincerx Pharma tied by winning 7 of the 14 factors compared between the two stocks.
Get Talphera News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talphera Competitors List
Related Companies and Tools
